You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The company announced the FDA has cleared its IND for ATA2271, allowing it to start a Phase I study of the autologous CAR T-cell therapy in advanced mesothelioma.
Anetumab ravtansine was well tolerated and there was "a positive trend" suggesting that high mesothelin expression may indicate which cancer patients benefit from BAY 94-9343.
In the hunt for an antigen in solid tumors that CAR T cells can target, researchers demonstrate the safety and efficacy profile of two such agents in early studies.
In a pan-cancer analysis, Lynch syndrome genes were mutated more often than anticipated in tumors with high or intermediate levels of microsatellite instability.